Physician profile
Mandip Kc
NPI 1487099685
$6,323.51
in general payments reported to CMS, 2019-2025
28 companies · $1,996 in 2025
The $1,996 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $156 · 2023: $1,792 · 2024: $2,379 · 2025: $1,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,167.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,631.49 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $889.93 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $569.24 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $423.94 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $418.90 | 2023-2025 | |
| Pfizer INC. | $256.32 | 2022-2025 | |
| Gilead Sciences, INC. | $241.09 | 2023-2025 | |
| Lilly USA, LLC | $235.81 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $231.13 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $210.27 | 2024-2025 | Voquezna |
| Celgene Corporation | $204.56 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $174.00 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $115.83 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $106.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $84.43 | 2023-2025 | Rebyota |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $80.76 | 2023-2025 | Ocaliva |
| Organon LLC | $73.96 | 2023-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $62.06 | 2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $57.19 | 2023-2024 | Dificid, Zinplava |
| Laborie Medical Technologies Corp. | $42.46 | 2023 | |
| Ironwood Pharmaceuticals, INC | $36.61 | 2024 | |
| Sandoz INC. | $32.60 | 2024 | Hyrimoz |
| Redhill Biopharma INC. | $29.26 | 2023 | Movantik, Aemcolo, Talicia |
| Medtronic, INC. | $27.36 | 2024 | Interstim |
| Fresenius Kabi USA, LLC | $26.41 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2023 | |
| Enterra Medical, INC. | $23.13 | 2025 | |
| Novo Nordisk INC | $13.65 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandip Kc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.